An ACE inhibitor and active metabolite of moexipril
Related Products
Pro-drug Form(s)
21255Moexipril (hydrochloride)
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Moexiprilat

Item No. 38047

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(3S)-2-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid
CAS Number
103775-14-0
Synonyms
  • RS 10029
Molecular Formula
C25H30N2O7
Formula Weight
470.5
Purity
≥95%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMSO: SolubleMethanol: Soluble
SMILES
C[C@H](N[C@H](C(O)=O)CCC1=CC=CC=C1)C(N2CC3=CC(OC)=C(OC)C=C3C[C@H]2C(O)=O)=O
InChi Code
InChI=1S/C25H30N2O7/c1-15(26-19(24(29)30)10-9-16-7-5-4-6-8-16)23(28)27-14-18-13-22(34-3)21(33-2)12-17(18)11-20(27)25(31)32/h4-8,12-13,15,19-20,26H,9-11,14H2,1-3H3,(H,29,30)(H,31,32)/t15-,19-,20-/m0/s1
InChi Key
CMPAGYDKASJORH-YSSFQJQWSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $101

    Add

    5 mg

    $376

    Add

    10 mg

    $700

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Moexiprilat is an inhibitor of angiotensin-converting enzyme (ACE; IC50 = 2.1 nM) and an active metabolite of the prodrug moexipril (Item No. 21255).1 It is formed from moexipril in vivo by side chain ester hydrolysis.2 Moexiprilat (10 nM) prevents the estrone- or angiotensin II-stimulated proliferation of primary neonatal rat cardiac fibroblasts.3 It reduces mean arterial blood pressure and increases the levels of atrial natriuretic peptide, a marker of hypertension, in ovariectomized mice when administered at a dose of 50 mg/kg per day.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Edling, O., Bao, G., Feelisch, M., et al. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: Pharmacological characterization and comparison with enalapril. J. Pharmacol. Exp. Ther. 275(2), 854-863 (1995).

    2. Cameron, R.T., Coleman, R.G., Day, J.P., et al. Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4). Biochem. Pharmacol. 85(9), 1297-1305 (2013).

    3. Grohé, C., Kahlert, S., Löbber, K., et al. Angiotensin converting enzyme inhibition modulates cardiac fibroblast growth. J. Hypertens. 16(3), 377-384 (1998).

    4. van Eickels, M., Schreckenberg, R., Doevendans, P.A., et al. The influence of oestrogen-deficiency and ACE inhibition on the progression of myocardial hypertrophy in spontaneously hypertensive rats. Eur. J. Heart Fail. 7(7), 1079-1084 (2005).